When was Apnimed founded?

Apnimed was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Apnimed located?

Apnimed is headquartered in Cambridge, United States. It is registered at 20 Holyoke Street Cambridge, MA 02138.

How many employees does Apnimed have?

As of Jun 30, 2026, the latest employee count at Apnimed is 92.

Is Apnimed a funded company?

Apnimed is a funded company, having raised a total of $249M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 07, 2019.

When was the latest funding round of Apnimed?

Apnimed's latest funding was a $***** Conventional Debt round on Apr 07, 2026, with participation from 1 investor.

Where does Apnimed rank among its competitors?

Apnimed ranks 1st amongst 24 active competitors, of which 7 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Apnimed, which secured $50M in Apr, 2026.

Who are the top competitors of Apnimed?

Apnimed's top competitors include Avadel Pharmaceuticals, Aculys and Nxera. Among them, Apnimed secured the most recent funding round in April, 2026.

Apnimed - 2026 Company Profile, Funding & Competitors

Company Details

Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.

Website: apnimed.com
Social
Email ID: *****@apnimed.com
Registered Address: 20 Holyoke Street Cambridge, MA 02138

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Public

Total Funding

$249M in 9 rounds

Latest Funding Round

Conventional Debt, Apr 07, 2026, $*****

Investors

Morningside & 7 more

Ranked

1^st among 24 active competitors

Employee Count

92 as on Jun 30, 2026

Similar Companies

Avadel Pharmaceuticals & 29 more

Exit Details

Public

View Apnimed's full profile

Apnimed is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Apnimed Inc CIN: 82-1910611 , United States, Active	Dec 31, 2016	-	13 (As on Dec 31, 2021)	-

Apnimed got listed on Jul 31, 2026.

Click here to take a look at Apnimed's IPO in detail

Apnimed has raised a total funding of $249M over 9 rounds. Its first funding round was on Aug 07, 2019. Its latest funding round was a Conventional Debt round on Apr 07, 2026 for $*****. 1 investor participated in its latest round. Apnimed has 8 institutional investors.

Here is the list of recent funding rounds of Apnimed:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 07, 2026	8913499	Conventional Debt	8926993	7996527	8306154	9682923
Mar 11, 2026	9712617	Series C	5590940	5075131	6207350	6883316
Sep 17, 2025	7276687	Conventional Debt	8881579	4244203	3576886	4825756

Access funding benchmarks and valuations. Sign up today!

View details of Apnimed's funding rounds and investors

Apnimed's employee count trend

Apnimed has 92 employees as of Jun 26. Here is Apnimed's employee count trend over the years:

Uncover Apnimed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Apnimed include Avadel Pharmaceuticals, Aculys and Nxera. Here is the list of Top 10 competitors of Apnimed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Apnimed 2017, Cambridge (United States), Public	Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea	$249M	Sectoral, Morningside & 6 others	59/100
2nd	Avadel Pharmaceuticals 1990, Dublin (Ireland), Acquired	Pharma company with proprietary drug delivery tools and drug for narcolepsy	-	RTW Investments, Venrock & 4 others	61/100
3rd	Aculys 2021, Fujisawa (Japan), Acquired	Developer of therapeutic medicines to treat neuropsychiatric disorders	$84M	SoftBank Vision Fund, Vision Pacific Life ... & 9 others	56/100
4th	Nxera 1990, Tokyo (Japan), Public	Developer of GPCR-targeted therapeutics to treat multiple diseases	-	OPF1 fund, Europa	55/100
5th	Mosanna Therapeutics 2022, Basel (Switzerland), Series A	Developer of small molecule therapeutics for sleep apnea	$80M	Forty51 Ventures, EQT & 6 others	47/100
6th	Neurim 1991, Tel Aviv (Israel), Unfunded	Drug discovery company focused on developing CNS drugs	-	-	42/100
7th	Circadian Therapeutics 2016, Oxford (United Kingdom), Seed	Developer of therapeutics to treat circadian rhythm disruption	$8.34M	University of Oxford, Oxford Science Enterprises ... & 7 others	37/100
8th	sofi 2020, London (United Kingdom), Funding Raised	Provider of natural remedy based mental & physical wellbeing services	-	Founders Factory, Access	36/100
9th	Lunair Minneapolis (United States), Series A	Developer of an implantable neurostimulation device for moderate-to-severe sleep apnea	$7.5M	SV Health Investors	34/100
10th	Imbrium Therapeutics 2019, Stamford (United States), Unfunded	Clinical-stage biopharmaceutical company developing novel therapeutics for unmet medical needs	-	-	30/100